Autologous Stem Cell Transplantation for Multiple Sclerosis

Autologous Stem Cell Transplantation for Multiple Sclerosis: Resetting the Immune System

The good news is that for most patients with multiple sclerosis (MS) today’s disease-modifying therapies can reduce relapses and slow the progression of disability. The a dilemma can arise. What happens if your multiple sclerosis continues to worsen even as your neurologist optimizes the best choices of medications for you? It’s a frightening possibility. Every new relapse is a concern. Will I lose another ability to do things? Will I become less independent? Is my quality of life be slipping away? The good news is that, even at this stage, there are more options to try.

For some patients with highly active multiple sclerosis, autologous hematopoietic stem cell transplantation (aHSCT) offers an entirely different treatment strategy. Rather than continuously suppressing the immune system with medication, this approach attempts to “reset” the immune system itself. Although autologous hematopoietic stem cell transplantation has been used to treat multiple sclerosis for well over twenty years, recent clinical studies suggest that many carefully selected patients can achieve prolonged remission, often with better disease control than conventional drug therapy.

An Entire Immune System Reboot to Treat Multiple Sclerosis

The goal of autologous hematopoietic stem cell transplantation is to reset the immune system. Some mistakenly assume that the stem cells repair damaged nerve tissue by replacing injured brain or spinal cord cells. Nope, that’s not how it works. The mechanism is much more clever than that.

Recall that multiple sclerosis develops when the immune system mistakenly attacks myelin, the protective “insulation” surrounding nerve fibers in the brain and spinal cord. This immune attack produces inflammation, damages myelin, and, over time, can injure the nerve fibers themselves.

During autologous hematopoietic stem cell transplantation, physicians first collect blood-forming stem cells from the patient’s bloodstream. Powerful chemotherapy is then used to eliminate much of the existing immune system, including many of the immune cells responsible for attacking myelin. The previously collected stem cells are then returned to the patient, where they rebuild a new immune system that is far less likely to attack the nervous system. When it works well, it’s a thing of beauty. The goal is not simply to suppress immune activity but to rebuild an immune system that no longer targets the brain and spinal cord.

Concerned young woman sitting on a couch talking with a medical nurse.

Could You Be a Candidate for Stem Cell Transplantation?

This is the question most patients want answered when their medications are failing them.

Today’s disease-modifying therapies control the disease quite well for most patients, which is a relief, because autologous hematopoietic stem cell transplantation is not the best treatment for everyone. Transplantation is a fairly intensive treatment.

The best candidates for transplantation are people who:

  • have relapsing-remitting multiple sclerosis (RRMS)
  • continue to experience relapses or develop new lesions on MRI scans despite treatment with highly effective disease-modifying therapies
  • are relatively young
  • still have active inflammatory disease processes
  • have not yet developed extensive irreversible neurological disability

Patients with primary progressive or secondary progressive multiple sclerosis generally experience less predictable results. Some patients with ongoing inflammatory disease may still benefit, but once progressive multiple sclerosis becomes dominated by irreversible nerve damage rather than active inflammation, transplantation becomes less effective.

Because autologous hematopoietic stem cell transplantation is a complex medical procedure requiring specialized expertise, it’s generally performed only at transplant centers that have developed a lot of experience working closely with neurologists specializing in multiple sclerosis.

In the Best-Choice Individuals, How Effective Is Transplantation?

Stem cell transplantation is very effective. The results have been remarkably impressive in several clinical studies.

The Multiple Sclerosis International Stem Cell Transplant Trial (MIST trial), published in 2019, remains one of the landmark randomized clinical trials in this field. It compared autologous hematopoietic stem cell transplantation with the best available disease-modifying therapies in patients with aggressive relapsing-remitting multiple sclerosis. Patients receiving transplantation experienced substantially fewer relapses, slower progression of disability, fewer new MRI lesions, and a better quality of life than those who continued conventional medical therapy.

And it isn’t just one study. Multiple investigations have now shown that many patients remain free of significant disease activity for years after transplantation. In several long-term studies, more than 70% of patients with relapsing-remitting MS had no worsening of disability ten years after treatment.

Smiling attractive middle-age woman with blond hair sitting in a pleasant surrounding on a gray couch holding a fancy wooden cane in her hand.

Perhaps most impressive of all, many patients required no additional disease-modifying therapy following successful transplantation. Now, THAT is a good outcome!

What About Side Effects and Adverse Reactions with Stem Cell Transplantation?

Although the procedure has become considerably safer through the past few years, autologous hematopoietic stem cell transplantation remains an intensive medical treatment.

Early transplantation studies carried significant risks, including treatment-related deaths. We’re pleased to report that those risks have declined substantially as transplant centers have gained experience, patient selection and care with patient selection has improved, and less toxic conditioning regimens have replaced older approaches.

Even so, the treatment is far from easy. Short-term complications include severe reductions in blood counts, infections, fever, and hospitalization. Longer-term complications may include thyroid disease, other autoimmune disorders, viral reactivation, infertility, and, rarely, secondary cancers. These risks explain why transplantation is generally reserved for patients whose disease remains highly active despite the best available medical therapy.

The “When” is Important, That Is, Timing Matters

One of the most important lessons from recent research is that timing is critical.

For patients whose disease continues to break through modern medications, every new relapse is a heartbreaker. The uncertainty about what the next MRI scan will show, or what will happen over the upcoming year, becomes a rough emotional rollercoaster. That is one reason why neurologists are increasingly interested in treatments capable of dramatically quieting the disease process before irreversible damage accumulates.

No Panic

The evidence consistently shows that transplantation works best before extensive permanent nerve damage has occurred. Waiting until years of irreversible injury have accumulated greatly reduces the likelihood that patients will regain lost neurological function.

For this reason, many multiple sclerosis specialists now recommend considering transplantation relatively early in carefully selected patients with aggressive relapsing-remitting disease who continue to have active disease despite high-efficacy medications, rather than viewing it strictly as a treatment of last resort.

More Good News, The Future Is Brighter

Researchers continue refining autologous hematopoietic stem cell transplantation by developing safer conditioning regimens, improving patient selection, and identifying which patients are most likely to benefit.

Scientists are also exploring newer immune therapies, including chimeric antigen receptor T-cell (CAR T-cell) therapy, which one day could provide highly targeted immune “reprogramming” with fewer side effects. Although these approaches remain experimental for multiple sclerosis, they illustrate just how rapidly this field continues to advance.

Autologous Hematopoietic Stem Cell Transplantation – A Final Comment

Autologous hematopoietic stem cell transplantation is one of the most exciting developments in the treatment of multiple sclerosis. It is not a cure, and it is not the best treatment for every patient. For carefully selected individuals with highly active relapsing-remitting multiple sclerosis, however, it can provide prolonged remissions, reduce the number of relapses, decrease new lesions appearing in the MRI scans, and slow the progression of disability more effectively than many conventional therapies.

woman with red hair sitting on the platform of an MRI machine "giving five" to the blond woman MRI technician in a white clinical coat

Only a decade ago, stem cell transplantation for multiple sclerosis was still viewed cautiously by many neurologists. Today, growing clinical evidence has moved it into mainstream discussions for carefully selected patients with aggressive disease. As transplant techniques continue to improve and long-term experience grows, autologous hematopoietic stem cell transplantation is likely to become an increasingly important part of the treatment toolbox. While it’s not cure, for some patients it has completely changed what physicians believed was possible.

Reference

Condamoor S, Vittayawacharin P, Sy M, Kongtim P, Ciurea SO. Autologous Stem Cell Transplantation for Multiple Sclerosis. Transplantation and Cellular Therapy. 2026;32:535-547. doi:10.1016/j.jtct.2025.12.1001.